The immuno-oncology race: myths and emerging realities
- PMID: 28148948
- DOI: 10.1038/nrd.2016.279
The immuno-oncology race: myths and emerging realities
Similar articles
-
American society of clinical oncology--41st annual meeting. Immunology.IDrugs. 2005 Jul;8(7):528-30. IDrugs. 2005. PMID: 15973554 No abstract available.
-
X chemotherapy, myth and realities.J Indian Med Assoc. 2005 Sep;103(9):489-90, 492, 494. J Indian Med Assoc. 2005. PMID: 16493871
-
American Association of Cancer Research Showcases Immunotherapy Advances.J Natl Cancer Inst. 2015 Aug 4;107(8):djv231. doi: 10.1093/jnci/djv231. Print 2015 Aug. J Natl Cancer Inst. 2015. PMID: 26243202 Free PMC article. No abstract available.
-
Checkpoint inhibitors: a cutting edge in oncology.Drugs Today (Barc). 2017 Jul;53(7):399-404. doi: 10.1358/dot.2017.53.7.2698995. Drugs Today (Barc). 2017. PMID: 28837184 Review.
-
"Therapeutic intent" in phase 1 oncology trials: a justifiable objective.Arch Intern Med. 2006 Jul 24;166(14):1446-8. doi: 10.1001/archinte.166.14.1446. Arch Intern Med. 2006. PMID: 16864753 Review. No abstract available.
Cited by
-
Immunotherapy in older patients with non-small cell lung cancer: Young International Society of Geriatric Oncology position paper.Br J Cancer. 2020 Sep;123(6):874-884. doi: 10.1038/s41416-020-0986-4. Epub 2020 Jul 22. Br J Cancer. 2020. PMID: 32694695 Free PMC article. Review.
-
Immune Checkpoint PD-1/PD-L1: Is There Life Beyond Antibodies?Angew Chem Int Ed Engl. 2018 Apr 23;57(18):4840-4848. doi: 10.1002/anie.201710407. Epub 2018 Feb 23. Angew Chem Int Ed Engl. 2018. PMID: 29178534 Free PMC article. Review.
-
Commentary on Perez et al.: How to create a 21st century adverse event reporting system.Clin Trials. 2017 Jun;14(3):234-236. doi: 10.1177/1740774517700641. Epub 2017 Mar 26. Clin Trials. 2017. PMID: 28345419 Free PMC article. No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
